GCG (Gene)

Organism:

Homo sapiens

Taxonomy (Entity type)

Synonyms:ENTREZ:2641, GCG, GLP-1, GLP1, GLP2, GRPP, HGNC:4191, MIM:138030, NM_002054, NP_002045, glucagon

Omim:OMIM:138030

Id:ENSG00000115263

Hgnc:HGNC:4191

Entrez:2641

Ensembl:ENSG00000115263

Description:glucagon

The protein encoded by this gene is actually a preproprotein that is cleaved into four distinct mature peptides. One of these, glucagon, is a pancreatic hormone that counteracts the glucose-lowering action of insulin by stimulating glycogenolysis and gluconeogenesis. Glucagon is a ligand for a specific G-protein linked receptor whose signalling pathway controls cell proliferation. Two of the other peptides are secreted from gut endocrine cells and promote nutrient absorption through distinct mechanisms. Finally, the fourth peptide is similar to glicentin, an active enteroglucagon. [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View GCG's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with GCG.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using GCG.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for GCG.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GCG.

Results found

Linked to

	Label	Description
	GSE131887 5 V 2 DOXYCYCLINE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 6 V 10 CRIZOTINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 6 V 5 CRIZOTINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE196343 metformin 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE199538 GSE199539 enzalutamide 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE153867 olaparib 6 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE109285 5 V 2 GLUCAGON MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE213845 EZH2 inhibition 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE213845 EZH2 inhibition 4 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE171837 3 V 1 BORTEZOMIB MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS

GSE131887 5 V 2 DOXYCYCLINE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 6 V 10 CRIZOTINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 6 V 5 CRIZOTINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE196343 metformin 1 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE199538 GSE199539 enzalutamide 2 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE153867 olaparib 6 v 4 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE109285 5 V 2 GLUCAGON MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE213845 EZH2 inhibition 2 v 0 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE213845 EZH2 inhibition 4 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE171837 3 V 1 BORTEZOMIB MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.